How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
45
PRLD Quote, Financials, Valuation and Earnings
Last price:
$1.85
Seasonality move
:
-23.7%
Day range:
$1.97 - $2.15
52-week range:
$0.61 - $4.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.29x
P/B ratio:
2.12x
Volume:
96.9K
Avg. volume:
537.6K
1-year change:
72.81%
Market cap:
$123.8M
Revenue:
$7M
EPS (TTM):
-$1.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
$20.5M | -$0.18 | 412.5% | -65.45% | $4.00 |
|
ACRS
Aclaris Therapeutics, Inc.
|
$1.9M | -$0.14 | 58.08% | -21.75% | $7.67 |
|
BLFS
BioLife Solutions, Inc.
|
$24M | $0.01 | 5.9% | -98.07% | $32.44 |
|
INCY
Incyte Corp.
|
$1.4B | $1.93 | 18.61% | 103.54% | $102.33 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$16.8M | -- | -7.76% | -- | $11.00 |
|
RLAY
Relay Therapeutics, Inc.
|
$5M | -$0.40 | -99.89% | -12.85% | $14.55 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
$1.97 | $4.00 | $123.8M | -- | $0.00 | 0% | 13.29x |
|
ACRS
Aclaris Therapeutics, Inc.
|
$3.51 | $7.67 | $380.3M | -- | $0.00 | 0% | 25.80x |
|
BLFS
BioLife Solutions, Inc.
|
$22.93 | $32.44 | $1.1B | -- | $0.00 | 0% | 10.97x |
|
INCY
Incyte Corp.
|
$101.18 | $102.33 | $19.9B | 16.97x | $0.00 | 0% | 4.18x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$2.06 | $11.00 | $165.7M | 29.64x | $0.00 | 0% | 2.62x |
|
RLAY
Relay Therapeutics, Inc.
|
$7.65 | $14.55 | $1.3B | -- | $0.00 | 0% | 155.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
23.37% | -0.793 | 21.91% | 3.02x |
|
ACRS
Aclaris Therapeutics, Inc.
|
1.83% | 2.539 | 1.09% | 3.92x |
|
BLFS
BioLife Solutions, Inc.
|
5.52% | 0.467 | 1.69% | 3.31x |
|
INCY
Incyte Corp.
|
0.88% | 1.667 | 0.25% | 2.86x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.674 | 4.58% | 2.00x |
|
RLAY
Relay Therapeutics, Inc.
|
5.2% | 2.761 | 3.7% | 18.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
$6.1M | -$20.4M | -90.83% | -106.36% | -314.12% | -$19.1M |
|
ACRS
Aclaris Therapeutics, Inc.
|
$850K | -$17M | -102.07% | -103.93% | -516.79% | -$11M |
|
BLFS
BioLife Solutions, Inc.
|
$17.2M | -$89K | -4.73% | -5.11% | -0.32% | $2.8M |
|
INCY
Incyte Corp.
|
$1.2B | $431.3M | 30.74% | 31.1% | 31.58% | $519.6M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
|
RLAY
Relay Therapeutics, Inc.
|
-$748K | -$80.4M | -38.91% | -41.21% | -11351.11% | -$62.1M |
Prelude Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PRLD or ACRS?
Aclaris Therapeutics, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of -442.98%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Aclaris Therapeutics, Inc.'s return on equity of -103.93%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M ACRSAclaris Therapeutics, Inc.25.77% -$0.12 $122.3M -
What do Analysts Say About PRLD or ACRS?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 103.05%. On the other hand Aclaris Therapeutics, Inc. has an analysts' consensus of $7.67 which suggests that it could grow by 118.42%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Prelude Therapeutics, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Prelude Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.2 0 0 ACRSAclaris Therapeutics, Inc.5 1 0 -
Is PRLD or ACRS More Risky?
Prelude Therapeutics, Inc. has a beta of 0.897, which suggesting that the stock is 10.343% less volatile than S&P 500. In comparison Aclaris Therapeutics, Inc. has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.421%.
-
Which is a Better Dividend Stock PRLD or ACRS?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aclaris Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Aclaris Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or ACRS?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are larger than Aclaris Therapeutics, Inc. quarterly revenues of $3.3M. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Aclaris Therapeutics, Inc.'s net income of -$14.6M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Aclaris Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 13.29x versus 25.80x for Aclaris Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.13.29x -- $6.5M -$19.7M ACRSAclaris Therapeutics, Inc.25.80x -- $3.3M -$14.6M
-
Which has Higher Returns PRLD or BLFS?
BioLife Solutions, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of 2.21%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat BioLife Solutions, Inc.'s return on equity of -5.11%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M -
What do Analysts Say About PRLD or BLFS?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 103.05%. On the other hand BioLife Solutions, Inc. has an analysts' consensus of $32.44 which suggests that it could grow by 29.88%. Given that Prelude Therapeutics, Inc. has higher upside potential than BioLife Solutions, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than BioLife Solutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.2 0 0 BLFSBioLife Solutions, Inc.9 0 0 -
Is PRLD or BLFS More Risky?
Prelude Therapeutics, Inc. has a beta of 0.897, which suggesting that the stock is 10.343% less volatile than S&P 500. In comparison BioLife Solutions, Inc. has a beta of 1.929, suggesting its more volatile than the S&P 500 by 92.869%.
-
Which is a Better Dividend Stock PRLD or BLFS?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLife Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. BioLife Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or BLFS?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are smaller than BioLife Solutions, Inc. quarterly revenues of $28.1M. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than BioLife Solutions, Inc.'s net income of $621K. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while BioLife Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 13.29x versus 10.97x for BioLife Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.13.29x -- $6.5M -$19.7M BLFSBioLife Solutions, Inc.10.97x -- $28.1M $621K
-
Which has Higher Returns PRLD or INCY?
Incyte Corp. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of 31.05%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Incyte Corp.'s return on equity of 31.1%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M INCYIncyte Corp.91.5% $2.11 $4.7B -
What do Analysts Say About PRLD or INCY?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 103.05%. On the other hand Incyte Corp. has an analysts' consensus of $102.33 which suggests that it could grow by 1.14%. Given that Prelude Therapeutics, Inc. has higher upside potential than Incyte Corp., analysts believe Prelude Therapeutics, Inc. is more attractive than Incyte Corp..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.2 0 0 INCYIncyte Corp.9 12 2 -
Is PRLD or INCY More Risky?
Prelude Therapeutics, Inc. has a beta of 0.897, which suggesting that the stock is 10.343% less volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.469%.
-
Which is a Better Dividend Stock PRLD or INCY?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or INCY?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are smaller than Incyte Corp. quarterly revenues of $1.4B. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Incyte Corp.'s net income of $424.2M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Incyte Corp.'s PE ratio is 16.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 13.29x versus 4.18x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.13.29x -- $6.5M -$19.7M INCYIncyte Corp.4.18x 16.97x $1.4B $424.2M
-
Which has Higher Returns PRLD or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of 13.19%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About PRLD or PLX?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 103.05%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 433.98%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Prelude Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Prelude Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.2 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is PRLD or PLX More Risky?
Prelude Therapeutics, Inc. has a beta of 0.897, which suggesting that the stock is 10.343% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.
-
Which is a Better Dividend Stock PRLD or PLX?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or PLX?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 29.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 13.29x versus 2.62x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.13.29x -- $6.5M -$19.7M PLXProtalix Biotherapeutics, Inc.2.62x 29.64x $17.9M $2.4M
-
Which has Higher Returns PRLD or RLAY?
Relay Therapeutics, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of -10395.13%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Relay Therapeutics, Inc.'s return on equity of -41.21%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M RLAYRelay Therapeutics, Inc.-48.01% -$0.43 $641M -
What do Analysts Say About PRLD or RLAY?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 103.05%. On the other hand Relay Therapeutics, Inc. has an analysts' consensus of $14.55 which suggests that it could grow by 90.14%. Given that Prelude Therapeutics, Inc. has higher upside potential than Relay Therapeutics, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Relay Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.2 0 0 RLAYRelay Therapeutics, Inc.10 0 0 -
Is PRLD or RLAY More Risky?
Prelude Therapeutics, Inc. has a beta of 0.897, which suggesting that the stock is 10.343% less volatile than S&P 500. In comparison Relay Therapeutics, Inc. has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.758%.
-
Which is a Better Dividend Stock PRLD or RLAY?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relay Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Relay Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or RLAY?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are larger than Relay Therapeutics, Inc. quarterly revenues of --. Prelude Therapeutics, Inc.'s net income of -$19.7M is higher than Relay Therapeutics, Inc.'s net income of -$74.1M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Relay Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 13.29x versus 155.69x for Relay Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.13.29x -- $6.5M -$19.7M RLAYRelay Therapeutics, Inc.155.69x -- -- -$74.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
